Delivery of siRNA Using CXCR4-targeted nanoparticles modulates tumor microenvironment and achieves a potent antitumor response in liver cancer

Molecular Therapy

Volumn 23, Issue 11, 2015, Pages 1772-1782

  Liu, Jia Yu ^a   Chiang, Tsaiyu ^a   Liu, Chun Hung ^a   Chern, Guann Gen ^a   Lin, Ts Ting ^a   Gao, Dong Yu ^a   Chen, Yunching ^a  

^a NATIONAL TSING HUA UNIVERSITY   (Taiwan)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CHEMOKINE RECEPTOR CXCR4; CHEMOKINE RECEPTOR CXCR4 ANTAGONIST; NANOPARTICLE; PLERIXAFOR; SMALL INTERFERING RNA; SORAFENIB; STROMAL CELL DERIVED FACTOR 1ALPHA; VASCULOTROPIN; ANGIOGENESIS INHIBITOR; CARBANILAMIDE DERIVATIVE; HETEROCYCLIC COMPOUND; NICOTINAMIDE; STROMAL CELL DERIVED FACTOR 1; VASCULOTROPIN A;

ADVANCED CANCER; ANIMAL EXPERIMENT; ANTIANGIOGENIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DOWN REGULATION; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; LIVER CANCER; LIVER CELL CARCINOMA; MALE; MOUSE; NONHUMAN; TREATMENT RESPONSE; TUMOR ASSOCIATED LEUKOCYTE; TUMOR GROWTH; TUMOR MICROENVIRONMENT; UPREGULATION; ANALOGS AND DERIVATIVES; ANIMAL; ANTAGONISTS AND INHIBITORS; C3H MOUSE; CARCINOMA, HEPATOCELLULAR; DISEASE COURSE; GENE THERAPY; GENETICS; LIVER NEOPLASMS; METABOLISM; NEOVASCULARIZATION, PATHOLOGIC; SIGNAL TRANSDUCTION; TUMOR CELL LINE; VASCULARIZATION;

ANGIOGENESIS INHIBITORS; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CHEMOKINE CXCL12; DISEASE PROGRESSION; GENETIC THERAPY; HETEROCYCLIC COMPOUNDS; HUMANS; LIVER NEOPLASMS; MALE; MICE; MICE, INBRED C3H; NANOPARTICLES; NEOVASCULARIZATION, PATHOLOGIC; NIACINAMIDE; PHENYLUREA COMPOUNDS; RECEPTORS, CXCR4; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84948718039     PISSN: 15250016     EISSN: 15250024     Source Type: Journal    
DOI: 10.1038/mt.2015.147     Document Type: Article

References (40)

1. Chen Y, Huang Y, Reiberger T, Duyverman AM, Huang P, Samuel R, et al. (2014). Differential effects of sorafenib on liver versus tumor fibrosis mediated by stromalderived factor 1 alpha/C-X-C receptor type 4 axis, and myeloid differentiation antigenpositive myeloid cell infiltration in mice. Hepatology 59: 1435-1447.
2. Hernandez-Gea V, Toffanin S, Friedman, SL, and Llovet JM (2013). Role of the microenvironment in the pathogenesis, and treatment of hepatocellular carcinoma. Gastroenterology 144: 512-527.
3. Hui CK, Leung N, Shek TW, Yao H, Lee WK, Lai JY, et al.; Hong Kong Liver Fibrosis Study Group. (2007). Sustained disease remission after spontaneous HBeAg seroconversion is associated with reduction in fibrosis progression in chronic hepatitis B Chinese patients. Hepatology 46: 690-698.
4. Luedde T, and Schwabe RF (2011). NF-?B in the liver-linking injury, fibrosis, and hepatocellular carcinoma. Nat Rev Gastroenterol Hepatol 8: 108-118.
5. Murakata A, Tanaka S, Mogushi K, Yasen M, Noguchi N, Irie T, et al. (2011). Gene expression signature of the gross morphology in hepatocellular carcinoma. Ann Surg 253: 94-100.
6. Sato K, Tanaka S, Mitsunori Y, Mogushi K, Yasen M, Aihara A, et al. (2013). Contrast-enhanced intraoperative ultrasonography for vascular imaging of hepatocellular carcinoma: clinical, and biological significance. Hepatology 57: 1436-1447.
7. Semela D, and Dufour JF (2004). Angiogenesis, and hepatocellular carcinoma. J Hepatol 41: 864-880.
8. Kerbel RS (2006). Antiangiogenic therapy: a universal chemosensitization strategy for cancer? Science 312: 1171-1175.
9. Meng H, Xing G, Sun B, Zhao F, Lei H, Li W, et al. (2010). Potent angiogenesis inhibition by the particulate form of fullerene derivatives. ACS Nano 4: 2773-2783.
10. Zhu AX, Duda DG, Sahani DV, and Jain RK (2011). HCC, and angiogenesis: possible targets, and future directions. Nat Rev Clin Oncol 8: 292-301.
11. Adnane L, Trail PA, Taylor I, and Wilhelm SM (2006). Sorafenib (BAY 43-9006, Nexavar), a dual-Action inhibitor that targets RAF/MEK/ERK pathway in tumor cells, and tyrosine kinases VEGFR/PDGFR in tumor vasculature. Methods Enzymol 407: 597-612.
12. Liu L, Cao Y, Chen C, Zhang X, McNabola A, Wilkie D, et al. (2006). Sorafenib blocks the RAF/MEK/ERK pathway, inhibits tumor angiogenesis, and induces tumor cell apoptosis in hepatocellular carcinoma model PLC/PRF/5. Cancer Res 66: 11851-11858.
13. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al.; SHARP Investigators Study Group. (2008). Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359: 378-390.
14. Mendez-Sanchez N, Vasquez-Fernandez F, Zamora-Valdes D, and Uribe M (2008). Sorafenib, a systemic therapy for hepatocellular carcinoma. Ann Hepatol 7: 46-51.
15. Xie B, Wang DH, and Spechler SJ (2012). Sorafenib for treatment of hepatocellular carcinoma: a systematic review. Dig Dis Sci 57: 1122-1129.
16. Carmeliet P, and Jain RK (2011). Molecular mechanisms, and clinical applications of angiogenesis. Nature 473: 298-307.
17. Jain RK (2013). Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol 31: 2205-2218.
18. Semenza GL (2012). Hypoxia-inducible factors in physiology, and medicine. Cell 148: 399-408.
19. Gao F, Liang B, Reddy ST, Farias-Eisner R, and Su X (2014). Role of inflammationassociated microenvironment in tumorigenesis, and metastasis. Curr Cancer Drug Targets 14: 30-45.
20. Kryczek I, Wei S, Keller E, Liu R, and Zou W (2007). Stroma-derived factor (SDF-1/ CXCL12), and human tumor pathogenesis. Am J Physiol Cell Physiol 292: C987-C995.
21. Gentilini A, Rombouts K, Galastri S, Caligiuri A, Mingarelli E, Mello T, et al. (2012). Role of the stromal-derived factor-1 (SDF-1)-CXCR4 axis in the interaction between hepatic stellate cells, and cholangiocarcinoma. J Hepatol 57: 813-820.
22. Kamba T, and McDonald DM (2007). Mechanisms of adverse effects of anti-VEGF therapy for cancer. Br J Cancer 96: 1788-1795.
23. Xiang ZL, Zeng ZC, Tang ZY, Fan J, Zhuang PY, Liang Y, et al. (2009). Chemokine receptor CXCR4 expression in hepatocellular carcinoma patients increases the risk of bone metastases, and poor survival. BMC Cancer 9: 176.
24. Yu M, Gang EJ, Parameswaran R, Stoddart S, Fei F, Schmidhuber S, et al. (2011). AMD3100 sensitizes acute lymphoblastic leukemia cells to chemotherapy in vivo. Blood Cancer J 1: e14.
25. Domanska UM, Timmer-Bosscha H, Nagengast WB, Oude Munnink TH, Kruizinga RC, Ananias HJ, et al. (2012). CXCR4 inhibition with AMD3100 sensitizes prostate cancer to docetaxel chemotherapy. Neoplasia 14: 709-718.
26. Teicher BA, and Fricker SP (2010). CXCL12 (SDF-1)/CXCR4 pathway in cancer. Clin Cancer Res 16: 2927-2931.
27. Chen Y, Ramjiawan RR, Reiberger T Ng MR, Hato T, Huang Y, et al. (2015). CXCR4 inhibition in tumor microenvironment facilitates anti-programmed death receptor-1 immunotherapy in sorafenib-Dreated hepatocellular carcinoma in mice. Hepatology 61: 1591-1602.
28. Jain RK (2005). Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy. Science 307: 58-62.
29. Huang Y, Yuan J, Righi E, Kamoun WS, Ancukiewicz M, Nezivar J, et al. (2012). Vascular normalizing doses of antiangiogenic treatment reprogram the immunosuppressive tumor microenvironment, and enhance immunotherapy. Proc Natl Acad Sci USA 109: 17561-17566.
30. Huang Y, Stylianopoulos T, Duda DG, Fukumura D, and Jain RK (2013). Benefits of vascular normalization are dose, and time dependent-letter. Cancer Res 73: 7144-7146.
31. Capece D, Fischietti M, Verzella D, Gaggiano A, Cicciarelli G, Tessitore A, et al. (2013). The inflammatory microenvironment in hepatocellular carcinoma: a pivotal role for tumor-Associated macrophages. Biomed Res Int 2013: 187204.
32. Zhou D, Huang C, Kong L, and Li J (2014). Novel therapeutic target of hepatocellular carcinoma by manipulation of macrophage colony-stimulating factor/ tumor-Associated macrophages axis in tumor microenvironment. Hepatol Res 44: E318-E319.
33. Tofilon PJ, Basic I, and Milas L (1985). Prediction of in vivo tumor response to chemotherapeutic agents by the in vitro sister chromatid exchange assay. Cancer Res 45: 2025-2030.
34. Kim W, Seong J Oh HJ, Koom WS, Choi KJ, and Yun CO (2011). A novel combination treatment of armed oncolytic adenovirus expressing IL-12, and GM-CSF with radiotherapy in murine hepatocarcinoma. J Radiat Res 52: 646-654.
35. Chen Y Wu JJ, and Huang L (2010). Nanoparticles targeted with NGR motif deliver c-myc siRNA, and doxorubicin for anticancer therapy. Mol Ther 18: 828-834.
36. Cui Z, Han SJ, Vangasseri DP, and Huang L (2005). Immunostimulation mechanism of LPD nanoparticle as a vaccine carrier. Mol Pharm 2: 22-28.
37. Li SD, Chen YC, Hackett MJ, and Huang L (2008). Tumor-Dargeted delivery of siRNA by self-Assembled nanoparticles. Mol Ther 16: 163-169.
38. Clifford RL, Deacon K, and Knox AJ (2008). Novel regulation of vascular endothelial growth factor-A (VEGF-A) by transforming growth factor (beta)1: requirement for Smads, (beta)-CATENIN, and GSK3(beta). J Biol Chem 283: 35337-35353.
39. Kim IS, Song YM, Cho TH, Park YD, Lee KB, Noh I, et al. (2008). In vitro response of primary human bone marrow stromal cells to recombinant human bone morphogenic protein-2 in the early, and late stages of osteoblast differentiation. Dev Growth Differ 50: 553-564.
40. Albrektsen T, Sorensen BB, Hjorto GM, Fleckner J, Rao LV, and Petersen LC (2007). Transcriptional program induced by factor VIIa-Dissue factor, PAR1, and PAR2 in MDAMB-231 cells. J Thromb Haemost 5: 1588-1597.